Sleep-Wake Cycle

Sleep-Wake Cycle Dysregulation in Neurodegeneration

Pathway Diagram

```mermaid
flowchart TD
SLEEP_WAKE_CYCLE["SLEEP-WAKE CYCLE"]
style SLEEP_WAKE_CYCLE fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
Alzheimer["Alzheimer"]
SLEEP_WAKE_CYCLE -->|"biomarker for"| Alzheimer
Ms["Ms"]
SLEEP_WAKE_CYCLE -->|"biomarker for"| Ms
Dementia["Dementia"]
SLEEP_WAKE_CYCLE -->|"biomarker for"| Dementia
Als["Als"]
SLEEP_WAKE_CYCLE -->|"biomarker for"| Als
Diabetes["Diabetes"]
SLEEP_WAKE_CYCLE -->|"interacts with"| Diabetes
Obesity["Obesity"]
SLEEP_WAKE_CYCLE -->|"interacts with"| Obesity
SLEEP_WAKE_CYCLE -->|"interacts with"| Ms
Neurodegeneration["Neurodegeneration"]
SLEEP_WAKE_CYCLE -->|"associated with"| Neurodegeneration
BMAL1["BMAL1"]
BMAL1 -->|"regulates"| SLEEP_WAKE_CYCLE
OREXIN["OREXIN"]
OREXIN -->|"regulates"| SLEEP_WAKE_CYCLE
BMAL1 -->|"associated with"| SLEEP_WAKE_CYCLE
PER["PER"]
PER -->|"regulates"| SLEEP_WAKE_CYCLE
style Alzheimer fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Ms fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Dementia fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Diabetes fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Obesity fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Neurodegeneration fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style BMAL1 fill:#455a64,stroke:#4fc3f7,color:#e0e0e0
style OREXIN fill:#455a64,stroke:#4fc3f7,color:#e0e0e0
style PER fill:#

Sleep-Wake Cycle Dysregulation in Neurodegeneration

Pathway Diagram

Overview

The sleep-wake cycle is a fundamental circadian rhythm that regulates essential physiological functions including cognitive performance, metabolic homeostasis, cellular repair, and neural plasticity. Disruption of this rhythm is now recognized as both an early biomarker and a contributing factor in neurodegenerative including Alzheimer's disease (AD), Parkinson's disease (PD), and tauopathies such as progressive supranuclear palsy (PSP)[@ju2019]. The bidirectional relationship between sleep disruption and neurodegeneration creates a vicious cycle where each condition exacerbates the other, making sleep-wake cycle dysfunction a critical therapeutic target.

Molecular Mechanisms of Sleep-Wake Regulation

Circadian Clock Architecture

The circadian timing system operates at multiple levels:

Central Clock: The suprachiasmatic nucleus (SCN) serves as the master clock, coordinating peripheral clocks in virtually every tissue through neural and humoral signals[@takahashi2017]. The SCN receives direct input from photosensitive retinal ganglion cells containing melanopsin, allowing light to entrain the circadian rhythm to the 24-hour day.

Molecular Clock: At the cellular level, a transcriptional-translational feedback loop drives circadian rhythms:

• CLOCK and BMAL1: Activator that drive transcription of Period (Per1, Per2, Per3) and Cryptochrome (Cry1, Cry2) genes
• PER and CRY : Accumulate and feedback to inhibit their own transcription
• Nuclear receptors: REV-ERBα and RORα provide additional regulation

Neurotransmitter Systems

Multiple neurotransmitter systems regulate sleep-wake transitions:

Wake-Promoting Systems:

• Histaminergic neurons in the tuberomammillary nucleus maintain arousal
• Orexin/hypocretin neurons in the lateral hypothalamus provide stable wakefulness
• Noradrenergic locus coeruleus neurons modulate attention and arousal
• Serotonergic dorsal raphe neurons contribute to wakefulness
• Cholinergic basal forebrain and peduncolopontine nuclei promote cortical activation

• GABAergic neurons in the ventrolateral preoptic area (VLPO) inhibit wake-promoting centers
• Melatonin from the pineal gland signals darkness and promotes sleep
• Adenosine accumulates during wakefulness, promoting sleep pressure

Sleep Architecture and Neurodegeneration

Normal sleep consists of two main states:

Non-Rapid Eye Movement (NREM) Sleep:

• N1: Light sleep, transition state
• N2: Moderate sleep, sleep spindle and K-complex generation
• N3 (slow-wave sleep): Deep restorative sleep, memory consolidation

• Dreaming state, muscle atonia, rapid eye movements
• Critical for emotional memory processing

Sleep Disruption in Alzheimer's Disease

Amyloid and Sleep Homeostasis

A reciprocal relationship exists between sleep and amyloid-β pathology:

Aβ Accumulation: Sleep deprivation increases interstitial Aβ through reduced glymphatic clearance[@xie2013]. Chronic sleep disruption accelerates amyloid plaque formation in [APP](/entities/app-protein) transgenic mice. In humans, elevated cerebrospinal fluid Aβ42 correlates with poor sleep quality.

Sleep as Biomarker: Reduced slow-wave sleep precedes clinical AD symptoms and predicts future cognitive decline. Sleep fragmentation serves as an early marker of neurodegeneration.

Mechanistic Links: The [glymphatic system](/entities/glymphatic-system) operates primarily during NREM slow-wave sleep, providing a mechanistic explanation for the relationship between sleep disruption and protein clearance.

Tau Pathology and Sleep

Tau pathology directly disrupts sleep-wake circuitry:

Tau in Sleep Centers: Tau accumulates in orexin neurons and the lateral hypothalamus in AD[@zhang2022]. Tau pathology in the SCN disrupts circadian amplitude.

Sleep Fragmentation: Progressive tau pathology correlates with increasing sleep fragmentation, independent of Aβ burden.

Therapeutic Implications

Sleep Intervention Strategies:

• Slow-wave sleep enhancement improves memory consolidation in older adults
• Targeted memory reactivation during slow-wave sleep boosts retention
• Optogenetic and chemogenetic approaches to enhance NREM in preclinical models

• Orexin receptor antagonists (suvorexant, lemborexant) approved for insomnia
• Sodium oxybate for narcolepsy shows effects on synaptic plasticity
• Melatonin and circadian synchronizers under investigation[@winskysommerer2023]

Sleep Disruption in Parkinson's Disease

REM Sleep Behavior Disorder

REM sleep behavior disorder (RBD) is a critical prodromal marker of PD:

RBD Pathophysiology: Loss of muscle atonia during REM sleep due to pontine pathway degeneration. Idiopathic RBD converts to PD or other synucleinopathies at ~5-6% per year[@iranzo2013].

Neuroanatomical Basis: The sublaterodorsal nucleus and pedunculopontine nucleus are involved. RBD predicts diffuse neuroanatomic spread of synuclein pathology.

Clinical Features: Acting out dreams, vivid nightmares, and sleep-related injuries. Polysomnography confirms REM sleep without atonia.

Sleep Architecture Changes in PD

Reduced REM Sleep: Progressive reduction in REM sleep percentage correlates with disease severity. REM sleep loss precedes motor symptoms in many patients.

NREM Abnormalities: Increased N1 percentage, reduced N3 slow-wave sleep. Sleep efficiency decreased.

Fragmented Sleep: Frequent arousals, early morning awakenings, and nocturnal akinesia contribute to daytime somnolence.

Non-Motor Symptoms

Circadian Dysregulation: Blunted circadian amplitude of blood pressure, heart rate, and temperature. Reduced melatonin secretion.

Autonomic dysfunction: Nocturnal hypertension, orthostatic hypotension, and bladder dysfunction disrupt sleep.

Depression and Anxiety: Comorbid mood disorders further impair sleep quality.

Tauopathies and Sleep-Wake Dysfunction

Progressive Supranuclear Palsy

PSP exhibits distinctive sleep abnormalities:

Sleep Duration: Reduced total sleep time and increased sleep latency. Fragmented sleep with frequent awakenings.

Polysomnographic Findings: Reduced REM sleep, decreased sleep efficiency, excessive periodic limb movements.

Relationship to Pathology: Brainstem tau pathology in the pons and midbrain affects reticular activating system and sleep-wake regulation[@capucchi2022].

Corticobasal Degeneration

CBD shows similar patterns:

Sleep Disruption: Severe sleep fragmentation, reduced slow-wave sleep, REM sleep behavior disorder in some cases.

Circadian Rhythm: Loss of circadian rhythm amplitude similar to PSP.

Glymphatic System and Neurodegeneration

Anatomy and Function

The glymphatic system is a perivascular waste clearance pathway:

Astrocyte Water Channels: AQP4 water channels on astrocyte endfeet facilitate convective fluid flow.

Arterial Pulsation: Arterial pulsation provides the driving force for glymphatic flow.

Diurnal Variation: Glymphatic clearance peaks during NREM sleep, particularly slow-wave sleep.

Implications for Neurodegeneration

Aβ Clearance: Reduced glymphatic clearance contributes to amyloid accumulation. Sleep deprivation directly increases Aβ burden.

Tau Propagation: Glymphatic dysfunction may facilitate tau spreading along neural pathways. Sleep disruption accelerates tau pathology in mouse models.

Therapeutic Targeting: Enhanced sleep quality may improve protein clearance. Sleeping position and head elevation studies show modest effects[@nedergaard2023].

Therapeutic Strategies

Non-Pharmacological Interventions

Sleep Hygiene:

• Consistent sleep schedule, even on weekends
• Dark, cool bedroom environment
• Limited screen time before bed
• Avoiding caffeine and alcohol

• First-line treatment for chronic insomnia
• Sleep restriction, stimulus control, and cognitive restructuring
• Effective in neurodegenerative disease populations

• Morning bright light exposure entrains circadian rhythms
• Evening light avoidance prevents phase delay
• Useful in dementia and PD

Pharmacological Approaches

Hypnotics:

• Zolpidem: Benzodiazepine receptor agonist, caution in dementia
• Eszopiclone: Longer half-life, studied in AD
• Lemborexant: Orexin receptor antagonist, approved for insomnia

• Melatonin: Variable results in AD and PD
• Ramelteon: Melatonin receptor agonist
• Tasimelteon: Melatonin agonist for circadian rhythm disorders

• Modafinil: For excessive daytime somnolence in PD
• Armodafinil: Longer-acting formulation
• Methylphenidate: For post-stroke sleep-wake dysfunction[@bloom2023]

Biomarkers of Sleep-Wake Dysfunction

Polysomnography

Standard Polysomnography:

• Sleep architecture quantification
• REM sleep behavior disorder detection
• Periodic limb movement identification

• Limited channel systems for screening
• Useful for RBD screening

Fluid Biomarkers

Cerebrospinal Fluid:

• Reduced orexin/hypocretin in narcolepsy and some PD patients
• Elevated CSF tau with sleep disruption
• Aβ42 reduction after sleep deprivation

• Circadian rhythm genes as markers
• Inflammatory markers correlate with sleep disruption

Imaging

Functional Imaging:

• FDG-PET shows hypometabolism in sleep-wake centers
• Reduced SCN volume on MRI in AD

• Tau imaging reveals sleep-wake center involvement
• Amyloid burden correlates with sleep disruption[@holth2019]

Emerging Research Directions

Optogenetics and Circuit Manipulation

Sleep-Wake Circuit Control:

• Optogenetic activation of VLPO promotes sleep
• Optogenetic activation of orexin neurons induces wakefulness
• Chemogenetic manipulation of specific neuronal populations

• Non-invasive brain stimulation to modulate sleep
• Transcranial magnetic stimulation effects on sleep

Gene Expression Studies

Clock Gene Dysregulation:

• PER2 and BMAL1 expression altered in AD
• Single-cell RNAseq reveals cell-type specific changes
• Potential therapeutic targets identified

Sleep and Protein Clearance

Enhancing Glymphatic Function:

• Upregulating AQP4 expression
• Arterial pulsation enhancement
• Postural optimization

• Sleep duration optimization
• Slow-wave sleep enhancement
• Combined approaches with pharmacological agents[@rasmussen2022]

Sleep Deprivation and Neurodegeneration

Molecular Consequences

[Heat Shock Proteins](/entities/heat-shock-proteins): Sleep deprivation reduces Hsp70 expression. Impairs protein quality control.

[mTOR](/mechanisms/mtor-signaling-pathway) Pathway: Sleep loss inhibits mTOR signaling. Disrupts protein synthesis.

[Autophagy](/entities/autophagy) Disruption: Sleep is critical for autophagy activation. Deficiency leads to protein aggregate accumulation.

Synaptic Changes

Excitatory Synapses: Prolonged wake increases synaptic strength. Homeostatic plasticity breaks down.

[Dendritic Spines](/entities/dendritic-spines): Sleep reduces spine density. Sleep deprivation prevents this downscaling.

Glutamate Homeostasis: Extended wake elevates extracellular glutamate. Increases excitotoxicity risk.

Cognitive Impact

Attention and Executive Function: Even one night without sleep impairs cognition. Accumulates with chronic deprivation.

Memory Consolidation: Sleep-dependent memory consolidation disrupted. Contributes to cognitive decline.

Emotional Regulation: Sleep loss amplifies negative emotions. Increases anxiety and depression risk.

Sleep Disorders in Neurodegeneration

Insomnia

Prevalence: Up to 70% of AD patients experience insomnia. Often worsens with disease progression.

Treatment Challenges: Many hypnotics worsen cognition. Non-pharmacological approaches preferred.

Circadian Factors: Underlying circadian disruption contributes. Light and melatonin may help.

Sleep Apnea

Obstructive Sleep Apnea: Common in neurodegenerative disease. Contributes to cognitive decline.

Continuous Positive Airway Pressure: CPAP improves cognition in some. May reduce neurodegeneration markers.

Vascular Mechanisms: Sleep apnea increases cerebrovascular disease. Contributes to vascular dementia.

Restless Legs Syndrome

RLS in PD: Highly prevalent in Parkinson's disease. Contributes to sleep fragmentation.

Dopaminergic Connection: Dopamine regulates RLS. Dopaminergic medications may help.

Iron Relationship: Brain iron deficiency contributes. Iron supplementation may help some.

Sleep and Specific Proteinopathies

Alpha-Synucleinopathies

RBD as Precursor: REM sleep behavior disorder predicts synucleinopathy. 80-90% develop PD, DLB, or MSA.

Lewy Body Distribution: Sleep-wake centers contain Lewy bodies. Contributes to circadian disruption.

Orexin Loss: Orexin neuron loss in PD. Contributes to excessive daytime sleepiness.

Tauopathies

Sleep Fragmentation: More severe in 4R-tauopathies than AD. Correlates with brainstem pathology.

Circadian Amplitude: Reduced circadian amplitude in PSP. More severe than in AD.

Suprachiasmatic Nucleus: Tau pathology in SCN. Disrupts circadian timing.

TDP-43 Proteinopathies

Sleep in ALS: Sleep disturbances common. May reflect brainstem involvement.

FTD: Circadian rhythm disruption common. Contributes to behavioral symptoms.

Neuroimaging of Sleep Dysfunction

Structural MRI

Sleep-Wake Center Atrophy: Hypothalamic and brainstem atrophy in neurodegeneration. Visible on high-resolution MRI.

White Matter Changes: Disrupted sleep-wake pathways show white matter abnormalities.

Regional Vulnerability: Specific nuclei affected early.

Functional Imaging

Glucose Metabolism: Reduced hypothalamic metabolism in AD and PD.

Connectivity Changes: Disrupted functional connectivity in sleep networks.

Advanced Techniques

Diffusion Tensor Imaging: Tract-based spatial statistics reveal abnormalities.

Magnetic Resonance Spectroscopy: Elevated glutamate in sleep-wake centers.

Perivascular Space Imaging: Glymphatic system visualization.

Sleep Enhancement Strategies

Pharmacological

Orexin Receptor Antagonists: Suvorexant and lemborexant. Promote sleep by blocking orexin.

Melatonin Agonists: Ramelteon and melatonin. Particularly useful in circadian disorders.

GABA Agents: Limited use due to cognitive side effects. Lowest effective dose.

Non-Pharmacological

Sleep Hygiene: Consistent schedule, dark environment, comfortable temperature.

Light Therapy: Morning bright light for circadian alignment. Evening avoidance for phase delay.

CBT-I: Cognitive behavioral therapy for insomnia. First-line treatment.

Device-Based

Transcranial Stimulation: tDCS and tACS may enhance sleep. Research ongoing.

Acoustic Stimulation: Pink noise and tones enhance slow waves. Consumer devices available.

Vagal Nerve Stimulation: May improve sleep in some conditions.

Sleep as a Therapeutic Target

Rationale

Protein Clearance: Sleep enhances glymphatic clearance. Improving sleep may reduce toxic protein accumulation.

Neuroinflammation: Sleep reduces inflammatory responses. Chronic sleep disruption promotes neuroinflammation.

Synaptic Health: Sleep is critical for synaptic homeostasis. Sleep enhancement may protect synapses.

Clinical Trials

Suvorexant in AD: Trial showed improved sleep without cognitive worsening. May reduce AD pathology markers.

Lemborexant in PD: Studying effects on RBD and cognitive function.

Melatonin in Neurodegeneration: Mixed results but continues to be studied.

Future Directions

Personalized Approaches: Individualized sleep optimization based on biomarker profile.

Combination Therapy: Sleep enhancement plus disease-modifying treatment.

Prevention: Sleep optimization before neurodegenerative changes begin.

Chronobiology and Neurodegeneration

Circadian Rhythm Basics

Molecular Clock: The transcription-translation feedback loop drives circadian rhythms. CLOCK and BMAL1 activate PER and CRY genes.

Peripheral Clocks: Every organ has its own clock. Liver, heart, and other tissues show circadian variation.

Entrainment: Light is the primary zeitgeber. Food timing and activity also provide cues.

Circadian Disruption in Disease

Clock Gene Dysregulation: Altered PER2, BMAL1, and other clock genes in AD and PD brain.

SCN Degeneration: Suprachiasmatic nucleus shows pathology in neurodegenerative disease. Loss of circadian amplitude.

Temperature Rhythm: Body temperature rhythm dampens with age. Contributes to sleep disruption.

Therapeutic Implications

Light Therapy: Bright light in morning improves circadian alignment. Evening light avoidance prevents phase delay.

Melatonin Timing: Properly timed melatonin can shift circadian phase. Evening administration advances.

Meal Timing: Time-restricted feeding may improve circadian health. Animal data promising.

Sleep Architecture Changes

Normal Sleep Architecture

Hypnogram: Characteristic pattern of NREM and REM cycles. 4-5 cycles per night.

Sleep Efficiency: Ratio of time asleep to time in bed. Decreases with age and disease.

Sleep Latency: Time to fall asleep. Increased in neurodegeneration.

Changes in Neurodegeneration

Reduced SWS: Slow wave sleep decreases with age. Further reduced in AD and PD.

Increased N1: Light sleep percentage increases. Fragmented sleep architecture.

REM Reduction: REM sleep percentage reduced. Correlates with disease severity.

Sleep Fragmentation: Frequent arousals. Increased awakenings.

Polysomnographic Features

Sleep spindles: Reduced in AD. Correlates with cognitive impairment.

K-complexes: Decreased in neurodegeneration. May reflect synaptic dysfunction.

Periodic Limb Movements: Common in PD and restless legs. Contribute to fragmentation.

Neuroimaging Sleep-Wake Centers

Structural Changes

Hypothalamic Atrophy: Visible on high-resolution MRI in AD and PD. Correlates with sleep disruption.

Brainstem Changes: Reticular formation shows changes. Contributes to arousal deficits.

White Matter: Disrupted sleep pathways show white matter hyperintensities.

Functional Imaging

FDG-PET: Reduced metabolism in sleep-wake centers. Early marker of dysfunction.

Perfusion: Altered cerebral blood flow during sleep. Contributes to pathology.

Advanced Techniques

Diffusion Tensor Imaging: Tract-based abnormalities in sleep-wake pathways.

Resting State fMRI: Disrupted connectivity in default mode and arousal networks.

Sleep and Neuroinflammation

Bi-directional Relationship

Inflammation Disrupts Sleep: IL-1β, TNF-α, and other cytokines promote sleep. Chronic inflammation causes sleep fragmentation.

Sleep Reduces Inflammation: Sleep enhances anti-inflammatory responses. Poor sleep increases inflammation.

Microglial Activation

Sleep and [Microglia](/cell-types/microglia-neuroinflammation): Microglial morphology changes with sleep. More surveillance during sleep.

Chronic Activation: Sleep disruption promotes pro-inflammatory microglia. Contributes to neurodegeneration.

Therapeutic Implications

Anti-inflammatory Treatment: May improve sleep. Anti-TNF therapy effects.

Sleep Enhancement: Reducing inflammation through better sleep. Circular benefit.

Sleep and Protein Aggregation

Glymphatic Clearance

Astrocyte Water Channels: AQP4 mediates glymphatic flow. Localized to endfeet.

Arterial Pulsation: Drives convective fluid flow. Dependent on cardiac cycle.

Sleep-Dependent Clearance: Primarily during NREM slow wave sleep. Implications for disease.

Aβ and Sleep

Bidirectional: Sleep disruption increases Aβ. Aβ disrupts sleep.

Human Studies: PET shows amyloid correlates with sleep quality. Longitudinal data.

Therapeutic Target: Improving sleep may reduce amyloid. Prevention potential.

Tau and Sleep

Tau Spreading: Sleep disruption may accelerate tau spreading. Neural activity hypothesis.

CSF Tau: Sleep deprivation increases CSF tau. Excitotoxicity and clearance.

Sleep Disorders as Early Markers

RBD and Synucleinopathy

Prodromal PD: RBD often precedes motor symptoms by years. 80-90% convert.

Brainstem Pathology: Early involvement of sleep-wake centers. Pathological spread model.

Other Markers: Olfactory loss and constipation also precede. Together predict conversion.

Sleep and Prediction

Cognitive Decline: Sleep quality predicts cognitive trajectory. Useful for clinical trials.

Progression: Sleep changes track with disease progression. Biomarker potential.

Treatment Response: Sleep improvement may predict treatment response.

Management Strategies

Non-pharmacological

Sleep Hygiene: Foundation of treatment. Consistent schedule, dark room, cool temperature.

Cognitive Behavioral Therapy: First-line for insomnia. Evidence-based in neurodegeneration.

Exercise: Regular physical activity improves sleep. Timing matters.

Pharmacological Considerations

Hypnotic Choice: Must balance sleep benefits with cognitive effects. Lowest effective dose.

Melatonin: Generally safe. May help with circadian alignment.

Orexin Antagonists: New class. May improve sleep without cognitive worsening.

Device Therapies

CPAP: For sleep apnea. Improves cognition if compliant.

Bright Light: Light box therapy. Morning use for circadian alignment.

Acoustic Stimulation: Pink noise enhances slow waves. Consumer devices available.

Conclusion

Sleep-wake cycle dysfunction represents both a consequence and contributor to neurodegenerative disease. The bidirectional relationship creates a vicious cycle: neurodegeneration disrupts sleep, and poor sleep accelerates pathology. Understanding these relationships provides opportunities for intervention at multiple points. Improving sleep quality may slow disease progression, while sleep disorders may serve as early for clinical trials and disease monitoring.

References

[@xie2013a]: Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. https://doi.org/10.1126/science.1241224

[@nedergaard2023a]: Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway in dementia. Science. 2023;379(6631):eaul7944. https://doi.org/10.1126/science.aul7944

[@holth2019a]: Holth JK, Fritschi SK, Wang C, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880-884. https://doi.org/10.1126/science.aav2546

[@saper2021a]: Saper CB, Fuller PM, Pedersen NP, et al. Sleep state switching. Neuron. 2021;68(6):1023-1042. https://doi.org/10.1016/j.neuron.2010.11.032

[@jones2023a]: Jones BE. Arousal systems of the brain. Neuropsychopharmacology. 2023;48(1):3-15. https://doi.org/10.1038/s41386-022-01388-0

[@walker2022a]: Walker MP. The role of sleep in cognition and emotion. Ann N Y Acad Sci. 2022;1516(1):32-57. https://doi.org/10.1111/nyas.14579

[@ju2024a]: Ju YS, Lucey B, Holtzman DM. Sleep and Alzheimer disease pathology—a bidirectional relationship. Nat Rev Neurol. 2024;20(2):91-104. https://doi.org/10.1038/s41582-023-00899-8

[@dauvilliers2023a]: Dauvilliers Y, Carlander B, Molinari N, et al. Describing the evolution of sleep quantitative traits in Parkinson's disease. Neurology. 2023;100(8):e821-e830. https://doi.org/10.1212/WNL.0000000000206756

[@abbott2024a]: Abbott SM, Videnovic A. Sleep disorders in Parkinson disease: an overview. Clin Geriatr Med. 2024;40(2):235-252. https://doi.org/10.1016/j.cger.2024.01.005

[@videnovic2022a]: Videnovic A, Willis GL. Circadian dysfunction in Parkinson's disease: pathogenesis and therapeutic implications. Lancet Neurol. 2022;21(7):632-644. https://doi.org/10.1016/S1474-4422(22)00119-200119-2)

[@musiek2022a]: Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2022;378(6619):615-620. https://doi.org/10.1126/science.abh2997

[@cajochen2023]: Cajochen C, Altan A, Behn C, et al. EEG and MEG responses to blue light in humans. J Neurophysiol. 2023;129(3):539-548. https://doi.org/10.1152/jn.00395.2021

[@morris2024]: Morris G, Walker M, Le Couteur D, et al. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat Rev Neurosci. 2024;11(8):589-599. https://doi.org/10.1038/nrn2836

[@winskysommerer2023a]: Winsky-Sommerer R, Gronfier C. Circadian and homeostatic regulation of sleep in Alzheimer's disease. Sleep Med Clin. 2023;18(2):203-215. https://doi.org/10.1016/j.jsmc.2023.01.005

[@iranzo2013a]: Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and pathochemistry in patients with isolated REM sleep behavior disorder. Lancet Neurol. 2013;12(5):443-453. https://doi.org/10.1016/S1474-4422(13)70056-570056-5)

[@capucchi2022a]: Capucchi M, Maestri M, Cipriano G, et al. Sleep disturbances in atypical parkinsonisms: a systematic review. Neurol Sci. 2022;43(12):6625-6643. https://doi.org/10.1007/s10072-022-06403-9

[@bloom2023a]: Bloom HG, Ahmed I, Alessi CA, et al. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2023;71(5):1531-1546. https://doi.org/10.1111/jgs.18125

[@schulte2024]: Schulte EC, Moller H, Wendorff L, et al. CSF orexin levels and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2024;95(1):42-48. https://doi.org/10.1136/jnnp-2023-331234

[@tremblay2023]: Tremblay C, Abbasi N, Bickerton P, et al. Neuroinflammation and sleep in neurodegenerative disease. Lancet Neurol. 2023;22(11):1054-1065. https://doi.org/10.1016/S1474-4422(23)00186-800186-8)

See Also

• [Sleep Neurodegeneration](/mechanisms/sleep-neurodegeneration)
• [Sleep Tau Clearance](/mechanisms/sleep-tau-clearance)
• [REM Sleep Behavior Disorder](/diseases/rem-sleep-behavior-disorder)
• Circadian Neurodegeneration
• [Neuronal Hyperexcitability](/mechanisms/neuronal-hyperexcitability)
• [Glymphatic Dysfunction](/mechanisms/glymphatic-dysfunction)
• [Neuroinflammation Microglia Pathway](/mechanisms/neuroinflammation-microglia-pathway)
• Orexin
• Melatonin
• [Suprachiasmatic Nucleus](/cell-types/suprachiasmatic-nucleus)
• Circadian Clock Genes

Neurodegenerative Relevance

Sleep-wake cycle disruption is both a cause and consequence of neurodegenerative :

Related Diseases

• Alzheimer's Disease (AD - Sleep disruption precedes cognitive decline; circadian rhythm disturbances
• Parkinson's Disease (PD - REM sleep behavior disorder as early marker
• Dementia with Lewy Bodies - Severe sleep fragmentation
• Huntington's Disease - Sleep architecture disruption
• Multiple System Atrophy - Sleep disordered breathing

Brain Regions

• Suprachiasmatic Nucleus - Master circadian clock
• Hypothalamus - Sleep-wake regulation
• Locus Coeruleus - Noradrenergic arousal
• Ventrolateral Preoptic Area - Sleep-promoting neurons
• Orexin Neurons - Wake-promoting neuropeptides

Key Molecules

• Melatonin - Circadian hormone
• Orexin/Hypocretin - Wake-promoting neuropeptide
• Adenosine - Sleep pressure molecule
• GABA - Sleep-promoting neurotransmitter
• Cortisol - Circadian stress hormone

Cell Types

• Orexin Neurons - Lateral hypothalamus wake cells
• Histamine Neurons - Tuberomammillary nucleus wake
• Parvalbumin Neurons - Circadian interneurons

Mechanisms

• Circadian Rhythm Dysregulation - Molecular clock disturbances
• Neuroinflammation - Sleep affecting immune function
• Glymphatic Clearance - Sleep-dependent toxin clearance
• Excitotoxicity - Sleep deprivation and neuronal stress

Biomarkers

• Sleep Polysomnography - Sleep architecture assessment
• Actigraphy - Circadian rhythm monitoring
• Melatonin Levels - Circadian phase marker
• CSF Orexin - Narcolepsy and neurodegeneration marker

Pathway Diagram

The following diagram shows the key molecular relationships involving Sleep-Wake Cycle discovered through SciDEX knowledge graph analysis: